SCHEMBL4167014

SCHEMBL4167014

CCN(CC)CCN(C)c1ccc(-c2nc3c(C(=O)Nc4ccccc4)ccnc3[nH]2)cc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GSK3B P49841 2/20 0.43
PTPN11 Q06124 1/20 0.39
CHEK1 O14757 1/20 0.39
MAP4K4 O95819 1/20 0.39
LCK P06239 1/20 0.39
CSF1R P07333 1/20 0.39
PIM1 P11309 1/20 0.39
PHKG2 P15735 1/20 0.39
MARK3 P27448 1/20 0.39
KDR P35968 1/20 0.39
FLT3 P36888 1/20 0.39
CLK2 P49760 1/20 0.39
GSK3A P49840 1/20 0.39
ITK Q08881 1/20 0.39
MAP4K2 Q12851 1/20 0.39
DYRK1A Q13627 1/20 0.39
MARK2 Q7KZI7 1/20 0.39
PIM3 Q86V86 1/20 0.39
MINK1 Q8N4C8 1/20 0.39
AURKB Q96GD4 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4148191 0.84 GSK3B (0.61) GSK3BCHEK1MAP4K4LCKCSF1R
SCHEMBL4167003 0.81 KDM4E (0.40) GSK3BCHEK1MAP4K4LCKCSF1R
SCHEMBL4152155 0.81 GSK3B (0.48) GSK3BPRMT5EGLN1ALDH1A1MAPT
SCHEMBL4169328 0.80 GSK3B (0.55) GSK3BCLK2TRPV1EGLN1ALDH1A1
SCHEMBL4144903 0.80 RAD52 (0.46) GSK3BAURKBPRMT5RAD52EGLN1
SCHEMBL4165141 0.79 GSK3B (0.53) GSK3BKDRGSK3ATRPV1RAD52
SCHEMBL4152144 0.78 GSK3B (0.60) GSK3BPRMT5KDM4EALDH1A1MAPT
SCHEMBL4152265 0.77 GSK3B (0.56) GSK3BCSF1REGLN1KDM4EALDH1A1
SCHEMBL4149979 0.75 PRMT5 (0.57) AURKBPRMT5
SCHEMBL4145731 0.75 GSK3B (0.57) GSK3BGSK3ARAD52MAPTUHRF1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090170847-A1 Imidazopyridine Derivatives Inhibiting Protein Kinase Activity, Method for the Preparation Thereof and Pharmaceutical Composition Containing Same YUYU PHARMA, INC. (KR) 2009-07-02 US claimed
EP-1984370-A1 IMIDAZOPYRIDINE DERIVATIVES INHIBITING PROTEIN KINASE ACTIVITY, METHOD FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITION CONTAINING SAME Crystalgenomics, Inc. (KR) 2008-10-29 EP claimed
WO-2007083978-A1 IMIDAZOPYRIDINE DERIVATIVES INHIBITING PROTEIN KINASE ACTIVITY, METHOD FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITION CONTAINING SAME CRYSTALGENOMICS, INC. (KR) 2007-07-26 WO claimed
US-20090170847-A1 Imidazopyridine Derivatives Inhibiting Protein Kinase Activity, Method for the Preparation Thereof and Pharmaceutical Composition Containing Same YUYU PHARMA, INC. (KR) 2009-07-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090170847-A1 Imidazopyridine Derivatives Inhibiting Protein Kinase Activity, Method for the Preparation Thereof and Pharmaceutical Composition Containing Same GSK3B, GSK3A, MAP3K3 GSK3B 1/4885PTPN11 1142/4885CHEK1 265/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.